Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
MIRM Stock Chart & Stats
$87.88
-$0.27(-0.64%)
At close: 4:00 PM EST
$87.88
-$0.27(-0.64%)
Day’s Range― - ―
52-Week Range$36.88 - $109.28
Previous CloseN/A
Volume92.82K
Average Volume (3M)839.15K
Market Cap
$5.30B
Enterprise Value$4.55B
Total Cash (Recent Filing)$383.33M
Total Debt (Recent Filing)$319.45M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Apr 30, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding60,341,618
10 Day Avg. Volume1,033,534
30 Day Avg. Volume839,155
Financial Highlights & Ratios
PEG Ratio2.28
Price to Book (P/B)12.60
Price to Sales (P/S)7.61
P/FCF Ratio72.26
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue8.73
Enterprise Value/Gross Profit10.81
Enterprise Value/Ebitda325.99
Forecast
1Y Price Target
$121.44Price Target Upside38.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$644.91M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyVolixibat showed a larger reduction in itch in mid-stage studies compared with a competing inhibitor, indicating a potential clinical advantage that could drive stronger adoption by hepatology specialists.
Commercial ExpansionThe approved tablet formulation could extend the product from pediatric liquid use into a larger adult population, supporting franchise growth through improved dosing convenience and patient adherence.
Pipeline And M&AAcquisition of Bluejay and addition of a late-stage hepatitis delta asset expand the pipeline into disease areas with no approved therapies, creating additional potential value drivers beyond the existing product.
Bears Say
Competitive PressureA competing IBAT inhibitor that is more advanced in the regulatory process could capture early market share and increase pricing and access pressure on volixibat.
Market Adoption And Enrollment RiskDifficulty identifying eligible patients and heavy reliance on one key product for revenue create execution risk for both trial enrollment and sustained commercial growth if uptake stalls.
Regulatory RiskRegulatory authorities are likely to require a confirmatory late-stage study for pruritus, which could delay approval and extend development risk for the program.
Mirum Pharmaceuticals News
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $36.88 and its highest was $109.28 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Mirum Pharmaceuticals Inc’s market cap is $5.30B.
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is Apr 30, 2026 which is in 35 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on Feb 25, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of $0.056 by -$0.156.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -0.34.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 60,341,618 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$0.1 in its last earnings report, missing expectations of $0.056. Following the earnings report the stock price went down -15.126%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MIRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$121.44 (38.19% Upside)
$121.44 (38.19% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 273.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.89%
12-Months-Change
Fundamentals
Return on Equity
-8.53%
Trailing 12-Months
Asset Growth
25.65%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
MIRM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Mirum Pharmaceuticals had a strong third quarter with significant revenue growth and positive net income for the first time. The company continues to advance its clinical pipeline and expand internationally. However, there are some challenges in revenue consistency and the adoption of genetic testing in certain segments.View all MIRM earnings summariesMIRM Stock 12 Month Forecast
Average Price Target
$121.44
▲(38.19% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Catalyst Pharma
―
Ultragenyx Pharmaceutical
―
ImmunityBio
―
Apellis Pharmaceuticals
―
Ownership Overview
Currently, No data available
---